SAREUM HOLDINGS PLC (SAR) — Annual General Meeting

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Q and A session. I'd now like to hand over to Executive Chairman, Doctor. Stephen Parker. Good morning. The The quorum being two members is present, and therefore, we may not proceed with this meeting. In common with recent senate general meetings, we've also opened a link through the investor meeting site in addition to the conventional meeting. I'm particularly grateful to those of you who have chosen to attend in person. We will deal with formal business meeting first, and there will be a presentation from doctor John Greene, our chief scientific officer, to provide an update on their research progress. We will then take questions to the floor in the usual manner around general meetings. Following following these questions, we will try to cut some or all of the questions posted via the IMC site Tim Mitchell, chief operating officer, Mike Owen, who chairs the moderation committee, and our finance manager, Chris Neil, who is over our side. Right now, I'd start the formal proceedings of this Annual General Meeting. The notice of Annual General Meeting was posted to shareholders on the 11/17/2025. Accordingly, the requisite notice of Annual General Meeting has been given. I propose, therefore, that with your consent, the notice at the general meeting should be taken as of late. Thank you. Before proceeding with all business of this meeting, I would now read a statement which was issued to the market this morning. The company has continued to advance its lead program, MSTC 18 o one, following the successful completion of its phase one clinical trial in 2024. Despite the temporary setback of the discontinuation of toxicology study, the company has made significant operational progress, including the appointment of a...